Xenobiotic-Induced Peroxisome Proliferation: Role of Tissue Specificity and Species Differences in Response in the Evaluation of the Implications for Human Health
- 1 January 1987
- book chapter
- Published by Springer Nature
- Vol. 10, 43-53
- https://doi.org/10.1007/978-3-642-71617-1_4
Abstract
Significant increases in the number of peroxisomes and in the activity of H2O2 generating peroxisomal fatty acid β-oxidation enzyme system occur in liver parenchymal cells of mice, rats and certain other species exposed to several structurally dissimilar hypolipidemic drugs and certain phthalateester plasticizers. These agents, referred to as peroxisome proliferators, are considered as novel hepatocarcinogenic agents in view of their non-mutagenic and non-genotoxic nature. The lack of mutagenicity of these agents combined with consistent coupling of proliferation of H2O2 generating peroxisomes led to the hypothesis that persistent proliferation of peroxisomes serves as an endogenous initiator of neoplastic transformation by inducing oxidative stress. The mechanism by which oxidative stress leads to neoplastic transformation is, however, not clear. This postulated link between peroxisome proliferation and carcinogenicity implies that tumors should develop only in organs displaying profound peroxisome proliferation. Current evidence indicates that maximal peroxisome proliferation is a tissue-specific phenomenon, restricted largely to the hepatocyte. This tissue-specific biological response suggests that interaction of these structurally dissimilar xenobiotics with a receptor(s) might be the mechanism responsible for peroxisome proliferation and the selective increase in the rate of transcription of peroxisomal fatty acid β-oxidation enzyme genes without significantly affecting the transcriptional rate of peroxisomal marker enzyme catalase gene. Identification and molecular characterization of peroxisome proliferator specific receptor(s) and elucidation of the mechanisms responsible for the differences in interspecies responses will be necessary for the evaluation of the implications for human health, since the carcinogenicity is not directly attributable to the chemical but to the adaptive responses of the host.Keywords
This publication has 30 references indexed in Scilit:
- Induction of fatty acid β-oxidation and peroxisome proliferation in the liver of rhesus monkeys by DL-040, a new hypolipidemic agentBiochemical Pharmacology, 1985
- 32P-Postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitroCarcinogenesis: Integrative Cancer Research, 1985
- Lack of covalent binding of peroxisome proliferators nafenopin and WY-14 643 to DNA in vivo and in vitroToxicology Letters, 1984
- Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compoundsBiochemical and Biophysical Research Communications, 1983
- Evaluation of Selected Hypolipidemic Agents for the Induction of Peroxisomal Enzymes and Peroxisome Proliferation in the Rat LiverHuman Toxicology, 1983
- Peroxisome proliferation in primary cultures of rat hepatocytesToxicology and Applied Pharmacology, 1983
- Carcinogenicity testing of phthalate esters and related compounds by the National Toxicology Program and the National Cancer Institute.Environmental Health Perspectives, 1982
- The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drugAtherosclerosis, 1979
- A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug.Proceedings of the National Academy of Sciences, 1976
- NATURE OF THE HEPATOMEGALIC EFFECT PRODUCED BY ETHYL-CHLOROPHENOXY-ISOBUTYRATE IN THE RATNature, 1965